Pertuzumab in breast cancer: A systematic review

Clinical Breast Cancer

Volumn 13, Issue 5, 2013, Pages 315-324

  Zagouri, Flora ^a,b   Sergentanis, Theodoros N ^b   Chrysikos, Dimosthenis ^b   Zografos, Constantine G ^b   Filipits, Martin ^a   Bartsch, Rupert ^a   Dimopoulos, Meletios Athanassios ^b   Psaltopoulou, Theodora ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Breast cancer; Perjeta; Pertuzumab; Systematic review

Indexed keywords

CAPECITABINE; DOCETAXEL; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ANTINEOPLASTIC ACTIVITY; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HEPATITIS; HUMAN; LEUKOPENIA; MEDLINE; MENSTRUAL IRREGULARITY; MONOTHERAPY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVIEW; RISK REDUCTION; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; VOMITING;

BREAST CANCER; PERJETA; PERTUZUMAB; SYSTEMATIC REVIEW;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS;

EID: 84883768754     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2013.05.002     Document Type: Review

References (50)

1. American Cancer Society Cancer Facts and Figures 2012 2012 American Cancer Society Atlanta Available at http://www.cancer.org/cancer/breastcancer/ detailedguide/breast-cancer-key-statistics Accessed May 21, 2013
2. E.A. Perez, E.H. Romond, and V.J. Suman Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 J Clin Oncol 29 2011 3366 3373
3. S.R. Morris, and L.A. Carey Trastuzumab and beyond: new possibilities for the treatment of HER2-positive breast cancer Oncology (Williston Park) 20 2006 1763 1776
4. H.S. Cho, K. Mason, and K.X. Ramyar Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab Nature 421 2003 756 760
5. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 2001 127 137
6. D. Harari, and Y. Yarden Molecular mechanisms underlying ErbB2/HER2 action in breast cancer Oncogene 19 2000 6102 6114
7. D.B. Agus, R.W. Akita, and W.D. Fox Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth Cancer Cell 2 2002 127 137
8. B.M. Fendly, M. Winget, and R.M. Hudziak Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product Cancer Res 50 1990 1550 1558
9. C.L. Arteaga ErbB-targeted therapeutic approaches in human cancer Exp Cell Res 284 2003 122 130
10. G. Schaefer, V.D. Fitzpatrick, and M.X. Sliwkowski Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175 Oncogene 15 1997 1385 1394
11. M.C. Franklin, K.D. Carey, and F.F. Vajdos Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex Cancer Cell 5 2004 317 328
12. A. Badache, and N.E. Hynes A new therapeutic antibody masks ErbB2 to its partners Cancer Cell 5 2004 299 301
13. R. Nahta, M.C. Hung, and F.J. Esteva The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells Cancer Res 64 2004 2343 2346
14. D.B. Agus, R.W. Akita, and W.D. Fox A potential role for activated HER-2 in prostate cancer Semin Oncol 27 2000 76 83 discussion 92-100
15. M. Malik, K. Totpal, and I. Balter Dose response studies of recombinant humanized monoclonal antibody 2C4 (pertuzumab) in tumor xenograft models Proc Am Assoc Cancer Res 44 2003 773
16. G.D. Lewis, J.A. Lofgren, and A.E. McMurtrey Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness Cancer Res 56 1996 1457 1465
17. T. Friess, S. Bauer, and A.M. Burger In vivo activity of recombinant humanised monoclonal antibody 2C4 in xenografts is independent of tumour type and degree of HER-2 overexpression 2002 EORTC-NCI-AACR Conference, Frankfurt, Germany abstract 953
18. N. Mendoza, G.L. Phillips, and J. Silva Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer Cancer Res 62 2002 5485 5488
19. M. Mann, H. Sheng, and J. Shao Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth Gastroenterology 120 2001 1713 1719
20. A. Liberati, D.G. Altman, and J. Tetzlaff The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration J Clin Epidemiol 62 2009 e1 34
21. D. Lu, H.A. Burris 3rd, and B. Wang Drug interaction potential of trastuzumab emtansine combined with pertuzumab in patients with HER2-positive metastatic breast cancer Curr Drug Metab 13 2012 911 922
22. J. Cortés, P. Fumoleau, and G.V. Bianchi Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer J Clin Oncol 30 2012 1594 1600
23. L. Gianni, T. Pienkowski, and Y.H. Im Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet Oncol 13 2012 25 32
24. J. Baselga, J. Cortés, and S.B. Kim Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 2012 109 119
25. L. Gianni, A. Lladó, and G. Bianchi Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 28 2010 1131 1137
26. J. Baselga, K.A. Gelmon, and S. Verma Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy J Clin Oncol 28 2010 1138 1144
27. N. Yamamoto, Y. Yamada, and Y. Fujiwara Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (pertuzumab, RO4368451) in Japanese patients with solid tumors Jpn J Clin Oncol 39 2009 260 266
28. C.C. Portera, J.M. Walshe, and D.R. Rosing Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer Clin Cancer Res 14 2008 2710 2716
29. D.B. Agus, M.S. Gordon, and C. Taylor Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer J Clin Oncol 23 2005 2534 2543
30. G. Attard, J. Kitzen, and S.P. Blagden A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours Br J Cancer 97 2007 1338 1343
31. J. Albanell, C. Montagut, and E.T. Jones A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors Clin Cancer Res 14 2008 2726 2731
32. K. Miller, L. Gianni, and F. Andre A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T) J Clin Oncol 28 2010 (15s):abstract 1012
33. S. Dawood, K. Broglio, and A.U. Buzdar Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review J Clin Oncol 28 2010 92 98
34. D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
35. M. Marty, F. Cognetti, and D. Maraninchi Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 2005 4265 4274
36. J. Baselga, and S.M. Swain CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer Clin Breast Cancer 10 2010 489 491
37. E.A. Perez, J.M. Lopez-Vega, and L. Del Mastro A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: an open-label, two-cohort, phase II study (VELVET) J Clin Oncol 2012 30s:abstract TPS653
38. M.F. Rimawi, C.J. Poole, and J.M. Ferrero Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: a randomized phase II study (PERTAIN) J Clin Oncol 2012 30s:abstract TPS654
39. J.M. Walshe, N. Denduluri, and A.W. Berman A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer Clin Breast Cancer 6 2006 535 539
40. J. Baselga, I. Bradbury, and H. Eidtmann Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet 379 2012 633 640
41. A. Schneeweiss, S. Chia, and T. Hickish Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: a randomized phase II study (TRYPHAENA) Cancer Res 71 2011 112s
42. G.W. De Keulenaer, K. Doggen, and K. Lemmens The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy Circ Res 106 2010 35 46
43. K. Okoshi, M. Nakayama, and X. Yan Neuregulins regulate cardiac parasympathetic activity: muscarinic modulation of beta-adrenergic activity in myocytes from mice with neuregulin-1 gene deletion Circulation 110 2004 713 717
44. M. Gassmann, F. Casagranda, and D. Orioli Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor Nature 378 1995 390 394
45. Y.Y. Zhao, D.R. Sawyer, and R.R. Baliga Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes J Biol Chem 273 1998 10261 10269
46. D. Lenihan, T. Suter, and M. Brammer Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab Ann Oncol 23 2012 791 800
47. K.M. Towndrow, N. Dybdal, and L.T. Nguyen Effects of chronic pertuzumab-mediated HER2 pathway inhibition March 21-25, 2004 Society of Toxicology, Baltimore, MD abstract 76
48. J.N. Rich, B.K. Rasheed, and H. Yan EGFR mutations and sensitivity to gefitinib N Engl J Med 351 2004 1260 1261
49. A.M. Drucker, S. Wu, and C.T. Dang Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis Breast Cancer Res Treat 135 2012 347 354
50. M. Edgerly, and T. Fojo Is there room for improvement in adverse event reporting in the era of targeted therapies? J Natl Cancer Inst 100 2008 240 242